Ghaffar 2020.

Study characteristics
Methods	Randomised controlled trial
Participants	Inclusion criteria: (quote:) "1. Age < 28 days; 2. Both genders; 3. Neonatal seizures as per operational definition for < 24 hours" Exclusion criteria: (quote:) "1. Who were already receiving anticonvulsants; 2. If seizures were due to correctable metabolic abnormalities (i.e. hypoglycaemia, hypocalcaemia, hypomagnesaemia, hyponatraemia); 3. Neonates with associated pulmonary, hepatic, renal, or cardiac dysfunction." PB group Number of patients: 30 Age (days, mean ± SD): 15.20 ± 5.62 14.90 ± 5.99 Male: 19 (63.3%) Duration of complaint (hours): 10.40 ± 4.83 Weight (kg): 4.056 ± 0.65 LEV group Number of patients: 30 Age (days, mean ± SD): 14.90 ± 5.99 Male: 19 (63.3%) Duration of complaint (hours): 11.433 ± 4.67 Weight (kg): 4.163 ± 0.64 The study was conducted at a single centre in Sialcot, Pakistan, from January 2019 to February 2020.
Interventions	PB group: (Quote:) "Intravenous loading dose maximum 40 mg/kg (initial loading dose 20 mg/kg reloading with 10 mg/kg for further 2 times) and maintenance dose 5 mg/kg." Given in infusion form in dilution in 15 mL normal saline over 15 minutes. LEV group: (Quote:) "Intravenous loading maximum 40 mg/kg (initially with 30 mg/kg then reloading with 10 mg/kg) and maintenance dose 20 mg/kg/day." Given in infusion form in dilution in 15 mL normal saline over 15 minutes. If seizures reoccur with maximum loading dose, then the patient was switched to other drug. Patient was continuously monitored and observed for reoccurrence of seizures within 24 hours.
Outcomes	(Quote:)"Efficacy as per operational definition was noted after 24 hours by the researcher himself." No further details were provided.
Notes	External funding sources were not mentioned in the publication. The authors reported not having potential conflicts of interest to disclose.